LivaNova PLC (LIVN) Analysts See $0.81 EPS

September 30, 2018 - By Vernon Prom


Analysts expect LivaNova PLC (NASDAQ:LIVN) to report $0.81 EPS on November, 1.They anticipate $0.12 EPS change or 12.90 % from last quarter’s $0.93 EPS. LIVN’s profit would be $39.36M giving it 38.26 P/E if the $0.81 EPS is correct. After having $0.96 EPS previously, LivaNova PLC’s analysts see -15.63 % EPS growth. The stock increased 0.91% or $1.12 during the last trading session, reaching $123.97. About 394,289 shares traded. LivaNova PLC (NASDAQ:LIVN) has risen 100.14% since September 30, 2017 and is uptrending. It has outperformed by 84.52% the S&P500.

LivaNova PLC, a medical device company, designs, develops, makes, and sells therapeutic solutions worldwide. The company has market cap of $6.02 billion. It operates in three businesses: Neuromodulation, Cardiac Surgery, and Cardiac Rhythm Management. It currently has negative earnings. The Neuromodulation business designs, develops, and markets its Vagus Nerve Stimulation Therapy System, an implantable device to treat drug-resistant epilepsy and treatment-resistant depression (TRD).

LivaNova PLC (NASDAQ:LIVN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: